Article
Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations.
Oncogene - 1 Jul 2021
Shariati Maryam, Evans Kurt W, Zheng Xiaofeng, Bristow Christopher A, Ng Patrick Kwok-Shing, Rizvi Yasmeen Q, Tapia Coya, Yang Fei, Carugo Alessandro, Heffernan Timothy P, Peoples Michael D, Tripathy Debu, Meric-Bernstam Funda
Abstract excerpt
Molecular alterations in the PI3K/AKT pathway occur frequently in hormone receptor-positive breast tumors. Patients with ER-positive, HER2-negative metastatic breast cancer are often treated with CDK4/6 inhibitors such as palbociclib in combination with endocrine therapy. Although this is an effective regimen, most patients ultimately progress. The purpose of this study was identifying synthetic lethality...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.